Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.46 | N/A | +2.93% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.46 | N/A | +2.93% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
AbbVie's earnings report shows a positive surprise in EPS, which contributed to a 3.15% increase in stock price following the announcement. The lack of revenue data and guidance may leave some investors cautious, but the positive EPS performance indicates strong underlying business health. Overall, the market reacted favorably to the earnings beat.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TESLA INC
Apr 22, 2025